 MIRAMAR, Fla., Nov. 18, 2020 GLOBE NEWSWIRE -- Generex Biotechnology Corporation OTCQB:GNBT is pleased to announce that the company has closed a 50 million Licensing and Development Agreement with a consortium of partners in China for the Ii-Key vaccine platform technology from Generex subsidiary NuGenerex Immuno-Oncology NGIO. 